CD73 inhibits antitumor immunity through the activation of adenosine receptors expressed on multiple immune subsets. CD73 also enhances tumor metastasis, although the nature of the immune subsets and adenosine receptor subtypes involved in this process are largely unknown. In this study, we revealed that A 2A /A 2B receptor antagonists were effective in reducing the metastasis of tumors expressing CD73 endogenously (4T1.2 breast tumors) and when CD73 was ectopically expressed (B16F10 melanoma). A 2A −/− mice were strongly protected against tumor metastasis, indicating that host A 2A receptors enhanced tumor metastasis. A 2A blockade enhanced natural killer (NK) cell maturation and cytotoxic function in vitro, reduced metastasis in a perforin-dependent manner, and enhanced NK cell expression of granzyme B in vivo, strongly suggesting that the antimetastatic effect of A 2A blockade was due to enhanced NK cell function. Interestingly, A 2B blockade had no effect on NK cell cytotoxicity, indicating that an NK cell-independent mechanism also contributed to the increased metastasis of CD73 + tumors. Our results thus revealed that CD73 promotes tumor metastasis through multiple mechanisms, including suppression of NK cell function. Furthermore, our data strongly suggest that A 2A or A 2B antagonists may be useful for the treatment of metastatic disease. Overall, our study has potential therapeutic implications given that A 2A /A 2B receptor antagonists have already entered clinical trials in other therapeutic settings.
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cancer metastasis | immunotherapy | tumor immunosuppression | innate immunity I t is now well-established that tumors use numerous immunosuppressive mechanisms to facilitate tumor growth (1, 2) . Landmark studies by Sitkovsky and colleagues established that one such mechanism is the catabolism of extracellular AMP into immunosuppressive adenosine (3, 4) . Extracellular adenosine is generated from adenosine monophosphate (AMP) by the ectoenzyme CD73 and binds to four known cell surface receptors (A 1 , A 2A , A 2B , and A 3 ) that are expressed on multiple immune subsets including T cells, natural killer (NK) cells, natural killer T cells, macrophages, dendritic cells, and myeloid-derived suppressor cells (MDSCs) (5) . The A 2A and A 2B receptor subtypes are essentially responsible for the immunosuppressive effects of adenosine. They share a common signaling pathway, both resulting in the activation of adenylate cyclase and the accumulation of intracellular cAMP. Extracellular AMP can be generated from ATP, an immuneactivating molecule, by the ectoenzyme CD39. Thus, CD73 and CD39 acting in concert can catabolize ATP into adenosine and therefore tip the balance from an immunostimulatory to an immunosuppressive microenvironment.
Physiologically, CD73 is expressed on endothelial cells, epithelial cells, and subsets of the immune system, including Tregs (5) . CD73 has been found to be up-regulated in several types of cancer and recently it has been shown to be a negative prognostic marker in triple negative breast cancer (5, 6) . Several preclinical studies indicate that targeting the CD73-adenosine pathway may be beneficial. Proof-of-concept studies demonstrated that targeting CD73 with an anti-CD73-blocking mAb could significantly delay tumor growth (7). This was due to enhanced antitumor immune T-cell responses as a result of attenuated A 2A -mediated immunosuppression. Subsequently, both host and tumor-expressed CD73 have been shown to be important in the suppression of antitumor T-cell responses. Indeed, CD73-deficient mice are resistant to several transplantable tumors and de novo carcinogenesis (8) (9) (10) (11) . On the other hand, specific targeting of CD73 on tumor cells using shRNA also significantly reduced tumor growth and prolonged survival (7, 12) .
Furthermore, the knockdown of CD73 expression on tumor cells reduced their ability to metastasize (7) . However, the mechanism by which CD73 promotes tumor metastasis is unclear. Understanding the mechanism by which CD73 increases tumor metastasis is vital to developing new strategies that target metastasis because there are no anti-CD73 mAbs currently in clinical development. The clinical relevance of this pathway is underlined by the correlation between CD73 expression and an increased risk of metastasis in breast cancer (13, 14) . Thus, the CD73 pathway has been proposed as a novel target for immunotherapy (15) .
In this current study, we found that CD73 promoted metastasis through the activation of both A 2A and A 2B receptors. A 2A blockade resulted in enhanced NK-cell activity in vitro and in vivo and reduced metastasis in a perforin-dependent manner. Thus, A 2A or A 2B antagonists, which have already been used in clinical trials in other disease settings (16) , are promising for the treatment of cancer metastasis for which there is a lack of effective options available.
Results
Tumor-CD73 Expression Promotes in Vivo Metastasis. Previous investigations in our laboratory suggested that the expression of CD73 on tumor cells could positively regulate metastasis (7) . To investigate whether CD73 expression was sufficient to increase the migratory properties of tumor cells, AT-3 breast adenocarcinoma and B16F10 melanoma cells (both CD73 − ) were transduced with retrovirus-encoding murine CD73 cDNA. CD73 expression on transduced AT-3 and B16F10 cells was at a level equivalent to 4T1.2 breast carcinoma cells, a metastatic cell line expressing high levels of CD73 (Fig. S1A) (7) . Ectopically expressed CD73 was enzymatically active as shown by the conversion of AMP to adenosine (Fig. S1B) . Despite the fact that ectopic CD73 expression did not modulate primary tumor growth of AT-3 (Fig.  1A ) or B16F10 tumors (Fig. 1B) , it significantly enhanced pulmonary metastasis when AT-3 cells were injected either s.c. (spontaneous metastasis) (Fig. 1C) or i.v. (experimental metastasis) (Fig. 1D) , and significantly promoted the experimental metastasis of B16F10 melanoma cells (Fig. 1E) .
Activation of A 2A Adenosine Receptors Enhances Metastasis Through
Suppression of the Antitumor Immune Response. We next examined the effect of 5′-(N-ethylcarboxamido)adenosine (NECA), a pan adenosine receptor agonist, on tumor metastasis to determine whether the prometastatic effect of CD73 could be replicated by adenosine receptor stimulation. NECA pretreatment was found to significantly increase the metastasis of B16F10 melanoma cells in WT mice (Fig. 2A) . The increased metastasis following NECA treatment of WT mice could be partially reversed with either PSB-1115 (an adenosine receptor A 2B antagonist) or SCH58261 (an adenosine receptor A 2A antagonist) ( Fig. 2A) (Fig. 4C) . Furthermore, the maturation of NK cells as shown by their up-regulation of CD27 following stimulation with IL-12 and IL-18 was inhibited by NECA (Fig. S2C) . Inhibition of NK cell cytokine production, maturation and upregulation of CD69 by NECA was reversible following A 2A blockade but not A 2B blockade. Similarly, the effects of NECA were replicated following treatment with the selective A 2A agonist CGS-21680. Moreover, NK cells from A 2A −/− mice were not modulated by NECA (Fig. 4D ). These data indicated that A 2A activation potently suppresses NK cell maturation and activation and suggested that A 2A blockade may reduce metastasis through enhancement of NK cell function. To explore this further, we evaluated the effect of A 2A blockade in perforin-deficient mice, in which NK cell cytolytic activity is impaired. In this setting, SCH58261 treatment was unable to reduce the metastasis of CD73 + B16F10 tumor cells ( (Fig. S3) ; however, a significantly higher proportion of NK cells isolated from mice treated with the A 2A antagonist SCH58261 expressed granzyme B compared with those isolated from vehicle or PSB-1115-treated mice ( Fig. 5 C and D) . These differences were also reflected by an increased mean fluorescence intensity (MFI) for granzyme B expression within the NK cells analyzed from SCH58261-treated mice (Fig. 5E ). Taken together, these data indicate that the expression of CD73 on tumor cells enhances metastasis through increased A 2A -mediated suppression of perforin-mediated NK cell cytotoxicity. Because A 2B blockade has previously been shown to modulate the differentiation of MDSCs and the function of macrophages and dendritic cells (18) (19) (20) , we investigated the impact of A 2B blockade on these immune subsets in the metastatic setting. A 2B blockade did not modulate the frequency of CD11b + (dendritic cells) subsets was unaltered in mice treated with the A 2B antagonist PSB-1115. Moreover, although A 2B activation has been shown to affect dendritic cell maturation in vitro (21), we found no differences in the expression of MHCII and CD86 on the pulmonary CD11b lo CD11c
+ subset (Fig. S4B) . The expression of these markers was also unaltered in the CD11b + F480 + macrophage cells (Fig. S4C ).
CD73 Can Promote Metastasis Independently of Adaptive Immunity.
Although our data show a clear role for the CD73:A 2A axis in the suppression of NK cells and therefore the increased metastasis of tumor cells, we hypothesized that CD73 may also promote tumor metastasis through other mechanisms. It has previously been observed that CD73 can increase the in vitro migration of tumor lines (7, 22, 23) and their adherence to extracellular matrix proteins (23, 24) . Indeed our own data suggest that A 2B blockade can reduce the metastasis of CD73 + tumors independently of effects on NK cells (Fig. 2E) . To investigate this further, we determined the effect of CD73 expression on the in vitro migration of AT-3 tumor cells. CD73 expression on AT-3 cells significantly enhanced their migration in the Boyden chamber assay compared with GFP control-transduced AT-3 cells (Figs.  6A and S5) . The enhanced migration of AT-3 CD73
+ tumor cells was significantly reduced by the addition of adenosine 5′-(α,β-methylene)diphosphate (APCP), a specific inhibitor of CD73 enzymatic activity (Fig. 6B) . To investigate if CD73
+ tumor cells had increased migratory potential in vivo, we investigated whether CD73 could promote the metastasis of tumors in immunocompromised mice. Indeed, expression of CD73 in both AT-3 and B16F10 tumor cells significantly enhanced metastasis in RAG −/− cγ −/− mice, although the effects were less marked than in WT mice ( mice, the fold increase in metastasis relative to GFP controls was significantly less than the fold increase in WT mice. Taken together, these data indicate that CD73 enhances metastasis through both immune-dependent and immune-independent pathways.
Discussion
The generation of adenosine by CD73 is an immunosuppressive mechanism that promotes primary tumor growth because of A 2A receptor-mediated suppression of antitumor T-cell responses (7, 8, (10) (11) (12) . CD73 also promotes metastasis, although the mechanisms underlying this have, to date, been largely unknown. In the current study, we have shown that expression of CD73 on tumor cells is sufficient to enhance tumor metastasis. Having found that the protective effect of A 2A blockade was dependent on host expression of A 2A receptors, we consequently found that the activation of A 2A receptors was associated with reduced activation, maturation, and cytokine production of NK cells in vitro. Moreover, A 2A blockade was ineffective in RAG −/− cγ −/− mice or perforin-deficient mice in which NK cells are absent or their cytolytic function is impaired. Although these results could potentially be explained through the modulation of other perforin-expressing immune subsets such as cytotoxic CD8 + T cells, it has previously been shown that CD8 + or CD4 + T-cell depletion has little effect on the metastasis of B16F10 cells (26) ; as a result, these results strongly imply a role for NK cellmediated cytotoxicity. Nevertheless, to demonstrate this directly, we isolated NK cells from tumor-bearing mice and detected significantly enhanced granzyme B expression in NK cells isolated from A 2A antagonist-treated mice. This is consistent with other in vitro studies demonstrating diminished NK cell cytotoxicity following A 2A stimulation (17, 27) . Taken together, our data indicate that suppression of NK cell function is an important mechanism governing the metastasis of CD73 + tumors in vivo. Notably, the activation of A 3 receptors has been shown to enhance NK cell activity in vitro and in vivo (28, 29) . Thus, A 2A blockade may enhance NK cell activity both directly by blocking an immunosuppressive receptor and indirectly by increasing the availability of adenosine for the activating A 3 receptor.
Although suppression of NK cell activity is clearly an important mechanism governing the metastasis of CD73
+ tumors, we observed that in contrast to A 2A blockade, A 2B blockade did not modulate the activation or cytokine production of NK cells. This indicates a distinct mechanism governing the antimetastatic effect of A 2B antagonism. A 2B activation is known to modulate several subsets of myeloid cells, including dendritic cells (21, (30) (31) (32) , macrophages (19, 33, 34) and MDSCs (20) . Notably, in the context of the primary tumor site, it has been reported that A 2B blockade could enhance the expression of CD86 on CD11b − dendritic cells and consequently induce more potent antitumor immune responses (18) . Similarly, the activation of the A 2B receptor has been shown to enhance the expansion of MDSCs in s.c. tumors (20) . However, we did not find any evidence of modulation of these subsets in the lungs of tumor-bearing mice, suggesting this is not the mechanism by which A 2B activation promotes tumor metastasis. Our results are consistent with recent work by another group suggesting that A 2B stimulation may enhance metastasis through an immuneindependent mechanism (35) . Knockdown of A 2B on tumor cells was reported to reduce the lung metastasis of breast cancer tumor cells by being associated with impaired formation of filopodia and reduced in vitro migratory and invasiveness (35) . This supports our previous observation that A 2B stimulation with a pharmacological agonist could enhance tumor cell migration in vitro (7) . Furthermore, the production of adenosine by CD73 was recently shown to enhance the adhesion of tumor cells to the extracellular matrix (36) . In the current study, we found that both NECA and CD73 enhanced the metastasis of B16F10 tumor cells in RAG −/− cγ −/− mice, albeit that the increase in metastasis was less pronounced than in WT mice. Increased metastasis in these immunocompromised mice was reversed by A 2B blockade, supporting the conclusion that the CD73-A 2B axis promotes metastasis through an immune-independent pathway. In our study, we demonstrated that ectopic expression of CD73 promoted the in vitro migration of AT-3 tumor cells. This is in agreement with a previous report using human breast cancer cell lines (22) and with our own study using CD73 knockdown on 4T1.2 tumor cells. The migration of CD73 + tumor cells was significantly reduced by APCP, implying a role for CD73-generated adenosine in tumor metastasis. Notably, however, the inhibition mediated by APCP was only partial despite the fact that we demonstrated that APCP was capable of almost completely abrogating the conversion of AMP into adenosine by CD73 at this concentration (Fig. S1) . Thus, we cannot exclude the possibility that CD73 enhances migration and, as a consequence, metastasis through an adenosine independent pathway. Indeed, CD73 was previously identified as lymphocytevascular adhesion protein 2, and implicated in the binding of lymphocytes to endothelial and dendritic cells (37) (38) (39) . In these studies, engagement of CD73 was found to trigger LFA-1 clustering and hence promote cell-cell interactions. Although the requirement for adenosine production by CD73 was not investigated in these studies, it has been shown that the enzymatic activity of CD73 was not required for its T-cell stimulatory function (40) . Thus, in future studies, it would be interesting to generate tumor cells expressing a kinase dead variant of CD73 to determine the potential impact on metastasis of CD73 in the absence of enhanced adenosine production.
In summary, we have identified a mechanism by which CD73 enhances the metastasis of tumors in vivo, involving the activation of A 2A receptors on NK cells and subsequent reduction in NK cell function. Our data have significant therapeutic potential in the treatment of tumor metastasis given that (i) CD73 expression was shown to be a predictor of metastasis in breast cancer patients (13) antagonist CVT-6883 has undergone a phase I trial (25) . All three compounds were safe and well-tolerated, indicating that a pathway to the clinic for drugs of this class maybe relatively straightforward. Because a link has been shown between CD73 expression and metastasis in breast cancer patients (13) , further investigation into the therapeutic potential of A 2A /A 2B blockade is warranted.
Materials and Methods
Cell Lines and Mice. The C57BL/6 mouse breast carcinoma cell line AT-3 was obtained from Trina Stewart (Griffith University, Brisbane, Australia) (44) Vectors and Tumor Cell Transduction. Murine CD73 cDNA (Open Biosystems) was cloned into the plasmid murine stem cell vector (pMSCV)-GFP retroviral vector. Retroviruses were made by transfection of either pMSCV-GFP or pMSCV-GFP-CD73 in combination with the pMD2.G envelope vector into HEK293gagpol cells using lipofectamine 2000 (Invitrogen) as per manufacturer's instructions. For ectopic CD73 expression, AT-3 and B16F10 tumor cells were transduced with retroviral supernatants in the presence of polybrene (4 μg/mL) and "spinfection" at 700 × g for 90 min. After four rounds of transduction, the cells were sorted based upon the expression of GFP.
Antibodies, Agonists, and Antagonists. NECA, CGS-21680, SCH58261, PSB-1115, and APCP were purchased from Sigma. BAY-60-6583 was gifted by Bayer. TY/23 (anti-CD73 mAb) antibody was produced in house from hybridoma cells provided by Linda Thompson (University of Oklahoma Health Sciences Center, Oklahoma City, OK).
Chemotaxis Assay. The migration of AT-3-GFP and AT-3-CD73 tumor cells was determined in a Boyden chamber assay as previously described (7).
Quantification of Metastatic Burden. B16F10 macrometastases on the surface of the lungs were counted using a dissecting microscope (Olympus SXZ7). Metastasis of 4T1.2 and AT-3 cells were determined in sections of the lung stained with hematoxylin and eosin. The number of metastases per section was counted.
NK Cell Cytotoxicity Assay. Splenic NK cells were isolated from WT C57BL/6 or BALB/c mice using the NK cell isolation kit II (Miltenyi Biotec) and were cultured 
